Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Triple negative • Ohio State University • NCI-CCC Breast Tumor Board Question • Breast Cancer, Non-metastatic
When would you offer anthracycline based adjuvant chemotherapy for a T1cN0 TNBC?
Does tumor size impact your recommendation? High grade? Young patient age?
Answer from: Medical Oncologist at Community Practice
Taxotere/Cytoxan (TC) 4 cycles would be a more reasonable standard adjuvant choice with proven DFS and OS advantage over AC (Jones et al, JCO 2009), and would avoid the risk of cardiotoxicity from Adriamycin. The data was demonstrated in older as well as younger patients from that trial. AC-T w...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
1.5-2 cm TNBC patients - I have no problem advocating 4 cycles of dose dense AC, as older data/multiple studies show a true survival advantage of 5-10% over no adjuvant Rx.
The question I wonder about and hope the academics here can answer, is how much survival benefit I'm adding with 12 weekly pac...